Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07856134) titled 'AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes' on Sept. 28.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Forefront Dermatology S.C
Condition:
Atopic Dermatitis
Intervention:
Biological: Lebrikizumab-lbkz
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: November 11, 2026
Target Sample Size: 250
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/stu...